Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir

Abstract

Adverse events were common, but were not significantly related to the presence of advanced fibrosis or cirrhosis. More critical monitoring in older and female patients with low platelets throughout treatment may reduce adverse event-related discontinuations.